| Jun'19 | Jun'18 | Jun'17 | Jun'16 | Jun'15 | Jun'14 | Jun'13 | Jun'12 | Jun'11 |
|---|---|---|---|---|---|---|---|---|
Revenues | ||||||||
2,018 | 444 | 394 | - | - | - | - | - | - |
Revenues | ||||||||
- | - | - | 948 | 1,851 | 205 | 1,007 | 1,277 | 520 |
Operating expenses: | ||||||||
Research and development (related party of $0, $217, $97 and $761), net of grant income of $0, $0, $0 and $37, respectively | ||||||||
5,474 | 3,986 | 4,117 | 3,156 | 3,495 | 1,898 | 3,431 | 4,981 | 3,083 |
Research and development - effect of Settlement Agreement (Note 8) | ||||||||
- | - | - | - | - | -1,041 | 0 | - | - |
Research and development - effect of amendment to Collaboration and License Agreement (Note 8) | ||||||||
- | - | - | - | - | -1,007 | 0 | - | - |
General and administrative (related party of $316, $288, $941 and $860) | ||||||||
12,332 | 10,685 | 10,551 | 7,685 | 5,022 | 3,888 | 4,243 | 5,623 | 7,090 |
General and administrative - effect of Settlement Agreement (Note 8) | ||||||||
- | - | - | - | - | -700 | 0 | - | - |
General and administrative - effect of amendment to Collaboration and License Agreement (Note 8) | ||||||||
- | - | - | - | - | 1,007 | 0 | - | - |
Total operating expenses | ||||||||
17,806 | 14,671 | 14,668 | 10,841 | 8,517 | 4,045 | 7,674 | 10,604 | 10,174 |
Operating loss | ||||||||
-15,788 | -14,227 | -14,274 | -9,893 | -6,666 | -3,840 | -6,667 | -9,327 | -9,654 |
Other income (expense): | ||||||||
Interest expense - related party | ||||||||
1,900 | 1,915 | 1,929 | 807 | 0 | - | 90 | 63 | 50 |
Interest income | ||||||||
75 | 15 | 39 | 22 | 9 | 8 | 9 | 12 | 12 |
Interest expense - effect of Settlement Agreement (Note 8) | ||||||||
- | - | - | - | - | -122 | 0 | - | - |
Royalty income | ||||||||
16 | 19 | 25 | 21 | 32 | 42 | 34 | 34 | 23 |
Other income (expenses) | ||||||||
- | - | - | - | - | 3 | -4 | - | - |
Loss on disposal of fixed assets | ||||||||
- | - | - | - | - | -1 | 0 | - | - |
Change in fair value of warrant derivative liability | ||||||||
- | - | - | - | - | - | 520 | 3,668 | -2,473 |
Total other income (expense) | ||||||||
-1,809 | -1,881 | -1,865 | -764 | 41 | 174 | 469 | 0 | -2,488 |
Consolidated net loss | ||||||||
-17,597 | -16,108 | -16,139 | -10,657 | -6,625 | - | - | - | - |
Net loss attributable to noncontrolling interest | ||||||||
-4 | -3 | -1,607 | -893 | 0 | - | - | - | - |
Net loss attributable to iBio, Inc. | ||||||||
-17,593 | -16,105 | -14,532 | -9,764 | -6,625 | -3,666 | -6,198 | -5,676 | -12,142 |
Preferred stock dividends- iBio CMO Preferred Tracking Stock | ||||||||
260 | 260 | 90 | 0 | - | - | - | - | - |
Net loss available to iBio, Inc. | ||||||||
-17,853 | -16,365 | -14,622 | -9,764 | -6,625 | - | - | - | - |
Comprehensive loss: | ||||||||
Consolidated net loss | ||||||||
-17,597 | -16,108 | -16,139 | -10,657 | -6,625 | - | - | - | - |
Net loss | ||||||||
-17,593 | -16,105 | -14,532 | -9,764 | -6,625 | -3,666 | -6,198 | -5,676 | -12,142 |
Other comprehensive loss - foreign currency translation adjustments | ||||||||
-1 | -1 | 0 | -4 | -25 | 0 | - | - | - |
Comprehensive loss | ||||||||
-17,598 | -16,109 | -16,139 | -10,661 | -6,650 | -3,666 | - | - | - |
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted | ||||||||
-0.94 | -1.54 | -1.64 | -0.12 | -0.09 | -0.06 | -0.13 | -0.14 | -0.39 |
Weighted-average common shares outstanding - basic and diluted | ||||||||
18,926 | 10,631 | 8,911 | 80,973 | 71,495 | 62,968 | 49,381 | 39 | 30,968 |